Search results for ''
J.P. Morgan week and WuXi Global Forum 2025 in San Francisco
13-16 January, 2025
San Francisco, CA, USA
ENYO Pharma will in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
ENYO Pharma will also take the opportunity to host an executive roundtable at WuXi-Global-Forum-2025 on the 14th of January to share our progress in drug development with Vonafexor in kidney diseases.
4th Rare & Genetic Kidney Disease Drug Development Summit
10-12 December 2024
Boston, MA, USA
ENYO Pharma will attend for the first time the 4th Rare & Genetic Kidney Disease Drug Development Summit that will be held in Boston, USA. The event will bring together industries, academic KOLs, and patient advocacy nephrology communities to discuss acceleration of clinical advancements in orphan kidney disease populations.
ENYO Pharma will present the ongoing ALPESTRIA-1 Phase 2 clinical trial with Vonafexor in patients with Alport syndrome.
MOSAIC – the Global NASH/MASH Trialist Forum
24-25 October 2024
Washington DC, USA
ENYO Pharma is attending the MOSAIC – Global NASH Trialist Forum 2024. The goal of the meeting was to define new integrative Cardiovascular-Kidney-Liver-Metabolic (CKLM) trials together with cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders.
Clinical trials
We are currently enrolling patients in the following clinical studies:
Phase 2 ALPESTRIA-1 clinical trial for Alport syndrome
We are aiming to preserve kidney function and reverse kidney damage with the investigational drug Vonafexor tested in our Phase 2 clinical study named “ALPESTRIA-1”: Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome. Learn more about ALPESTRIA-1 clinical study
Latest Press Release 